Exchange: NASDAQ·Updated 07:30 PM EDT

RCKT News

News
all
press releases
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights
The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.
Stocktwits
More News
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced alignment with the U.S. Food and Drug Administration (FDA) on...
Business Wire
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced that the Company will participate in the 2026 Cantor Global...
Business Wire
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
Zacks
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended...
Business Wire
Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial
Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.read more...
Benzinga
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced a positive clinical safety update regarding...
Business Wire

Advertisement|Remove ads.